Skip to main content
Erschienen in: Wiener klinische Wochenschrift 17-18/2023

12.06.2023 | original article

Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws

verfasst von: Shenghong Wu, Yu Wang, Jinfeng Zhang, Zhonghui He, Yuanjue Sun, Ming Ye

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2023

Einloggen, um Zugang zu erhalten

Summary

Background

Osteosarcoma of the jaw is one of the rare malignancies and the role of postoperative adjuvant therapy is unclear. This study explored the efficacy of adjuvant therapy after radical surgery for primary osteosarcoma of the jaw.

Methods

The data were retrospectively analyzed from May 2012 to June 2021. The recurrence rate, disease-free survival (DFS) and 5‑year overall survival (OS) rate were calculated by Kaplan-Meier method. Intergroup rates were examined by chi-square test.

Results

125 post-radical surgery patients were included. The median follow-up time was 66 months. Forty five cases suffered recurrence. The recurrence rate was 36.0%, and the 5‑year OS rate was 68.8%. In the adjuvant treatment group, twenty eight of 99 patients experienced disease progression. In the surgical treatment alone group, seventeen of 26 patients experienced disease progression. The recurrence rates in the two groups were 28.3 and 65.4%, respectively (χ2 = 12.303, p < 0.001). The 5‑year OS rate was 75.8 and 42.3%, respectively (χ2 = 10.734, p = 0.001). The median DFS of the relapse patients was 15.1 months (95% CI:13.00–17.20 months), and the 5‑year OS rate was 40.0%. Among them, 28 patients received adjuvant therapy while 17 received surgical treatment alone. The median DFS was 15.7 and 11.5 months, respectively, p = 0.024. The median OS was 69.6 months (95% CI 55.69 ~ 83.51 months) and 62.4 months (95% CI 49.06 ~ 75.74 months), respectively(p = 0.034).

Conclusion

Adjuvant therapy is one of the effective measures to reduce the relapse rate and improve OS after radical surgery for primary osteosarcoma of the jaw.
Literatur
2.
Zurück zum Zitat Clark JL, Unni KK, Dahlin DC, et al. Osteosarcoma of the jaw. Cancer. 1983;51(12):2311–6. https://doi.org/10.1002/1097-0142(19830615)51:12〈2311::aid-cncr2820511224〉3.0.co;2‑z. PMID: 6573939.CrossRefPubMed Clark JL, Unni KK, Dahlin DC, et al. Osteosarcoma of the jaw. Cancer. 1983;51(12):2311–6. https://​doi.​org/​10.​1002/​1097-0142(19830615)51:12〈2311::aid-cncr2820511224〉3.0.co;2‑z. PMID: 6573939.CrossRefPubMed
18.
Zurück zum Zitat Laskar S, Basu A, Muckaden MA, D’Cruz A, Pai S, Jambhekar N, Tike P, Shrivastava SK. Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck. 2008;30(8):1020–6. https://doi.org/10.1002/hed.20820.CrossRefPubMed Laskar S, Basu A, Muckaden MA, D’Cruz A, Pai S, Jambhekar N, Tike P, Shrivastava SK. Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck. 2008;30(8):1020–6. https://​doi.​org/​10.​1002/​hed.​20820.CrossRefPubMed
25.
Metadaten
Titel
Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws
verfasst von
Shenghong Wu
Yu Wang
Jinfeng Zhang
Zhonghui He
Yuanjue Sun
Ming Ye
Publikationsdatum
12.06.2023
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 17-18/2023
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-023-02228-x

Weitere Artikel der Ausgabe 17-18/2023

Wiener klinische Wochenschrift 17-18/2023 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month

MUW researcher of the month

MUW researcher of the month